- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
All News
FDA Grants Orphan Drug Designation to PT886 for Pancreatic Cancer
July 01, 2022
PT886 was granted orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.
Factors Influencing Treatment Options for Stage 1B Grade 3 Endometrial Cancer
July 01, 2022
David Barrington, MD, discusses the key takeaways regarding the factors associated with variation of adjuvant treatments for patients with stage 1B, grade 3 endometrial cancer.
Reviewing Erlotinib/Binimetinib Combo in EGFR+ or KRAS+ NSCLC
June 30, 2022
Andreas Saltos, MD, discusses the key takeaways of the phase 1/1b clinical trial exploring the use of binimetinib plus erlotinib in patients with non–small cell lung cancer harboring either KRAS or EGFR mutations.
Behind the FDA Approval: Liso-Cel for R/R Large B-Cell Lymphoma
June 30, 2022
In an interview with Targeted Oncology, Manali Kamdar, discussed the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma, and how community oncologists should approach patient referrals and post-treatment care.
Botensilimab Plus Balstilimab Shows Remarkable Activity in MSS CRC
June 30, 2022
Botensilimab and balstilimab use in patients with microsatellite stable colorectal cancer showed strong durability and superior efficacy, according to expanded data from the phase 1b C-800 study
First Patient Dosed in Study of RMC-6236 in KRAS-Driven Advanced Solid Tumors
June 30, 2022
A phase 1/1b monotherapy clinical trial of RMC-6236 for the treatment of patients with advanced solid tumors driven by a variety of RAS mutations has dosed its first patient.
Ruxolitinib Shows Superiority Over BAT in Second-Line, Inadequately-Controlled Polycythemia Vera
June 29, 2022
Five-year data from the RESPONSE-2 study combined with prior RESPONSE study results show that there is an option for the roughly 40% of patients with polycythemia vera who become intolerant or resistant to hydroxyurea.
Ibrutinib/Venetoclax May Decrease Development of Resistance Mutations in Patients With CLL
June 29, 2022
Findings from an analysis of the CAPTIVATE study imply that ibrutinib plus venetoclax may allow for effective subsequent retreatment with ibrutinib and/or venetoclax and enhance clinical benefit.
Treatment Options Continue to Evolve for Hematologic Malignancies
June 29, 2022
During an interview with Targeted Oncology, Gunther Koehne, MD, PhD, explained the need to get experts together and discuss the increased activity of new developments for hematologic malignancies.
FDA Grants Breakthrough Therapy Designation to Talquetamab for R/R Myeloma
June 29, 2022
The FDA has granted breakthrough therapy designation to talquetamab for the treatment of previously-treated adult patients with relapsed or refractory multiple myeloma based on positive results from the phase 1/2 MonumenTAL-1 study.